What Keal Treats: Main Uses and Benefits

Supportive care is relevant for managing distressing symptoms and helping contribute to a patient’s general comfort. Keal is commonly used in areas where short-term symptom management is appropriate, assisting patients during phases of heightened symptomatic burden.

Keal is generally applied across conditions characterized by episodic or fluctuating symptom patterns and is relevant in scenarios where symptoms interfere with daily functioning or create noticeable physiological strain. It helps address symptom clusters that appear suddenly or intensify over time, such as those related to physical discomfort, systemic imbalance, or acute episodes. It helps support patients during difficult episodes, easing distress and assisting with maintaining a sense of stability.

“The medication may assist with managing temporary symptomatic discomfort in various situations.”

Quick Fact: Relief for Episodic Discomfort

Keal is relevant for managing acute or disruptive episodes and associated manifestations when symptoms become temporarily overwhelming.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Keal?

The official population eligibility for Keal (sucralfate) is defined by regulatory documents, which establish clear restrictions based on patient age, underlying conditions, and physiological status.

Eligibility Scope

Population Restrictions

Official labeling states that the safety and effectiveness of Keal have not been established in the pediatric population (under 18 years of age). For pregnant women, the drug is classified as Pregnancy Category B and should be used only if clearly needed. Caution must be exercised when the medicine is administered to nursing mothers, as it is not known if the drug is excreted in human milk. Furthermore, use is restricted in patients with underlying conditions that may predispose to bezoar formation, such as delayed gastric emptying or use with concomitant enteral tube feedings.

Interactions with other medicines and products

Keal (sucralfate) exhibits two primary, officially documented interaction patterns: pharmacokinetic reduction of absorption and a pharmacodynamic additive effect.

The pharmacokinetic interaction is nonsystemic, resulting from sucralfate binding to concomitant medicinal products in the gastrointestinal tract. This binding reduces the extent of absorption (bioavailability) for single doses of several agents. Explicitly listed medicines affected include cimetidine, digoxin, fluoroquinolone antibiotics, l-thyroxine (levothyroxine), and phenytoin. To prevent this reduction in absorption, the concomitant medication must be administered 2 hours before Keal.

The pharmacodynamic interaction involves the risk of an increased total body burden of aluminum when Keal, an aluminum salt, is co-administered with other aluminum-containing products, such as antacids. Antacids should not be taken within 30 minutes before or after Keal.

A population-specific interaction note exists for patients with chronic renal failure or those on dialysis. Because these patients have impaired aluminum excretion, the use of Keal carries an increased risk of aluminum accumulation and toxicity. Furthermore, simultaneous administration of Keal with food can reduce its local efficacy, and regulatory reports note a risk of bezoar formation when the suspension is given with enteral tube feedings.

Keal's mechanism centers on a local, physicochemical dependency, requiring a gastric pH typically below 4.0 for activation. In this environment, the drug polymerizes into a viscous, polyanionic gel. This specialized gel selectively adheres via electrostatic binding to positively charged proteins exposed at the site of mucosal damage, creating a localized physical barrier. This shielding impedes the chemical aggression from hydrogen ions and bile salts, while also inhibiting the proteolytic activity of the enzyme Pepsin A. Beyond this physical defense, the compound modulates local intrinsic defense mechanisms. It stimulates the localized release of Prostaglandin E2 ( PGE2) and protects endogenous Growth Factors (EGF, FGF2) by binding them locally at the tissue defect. This action affects factors involved in tissue repair processes, leading to the physiological consequence of accelerated epithelial cell renewal and increasing the native production of protective mucus and bicarbonate ions. The entire mechanism is strictly peripheral and topical, with no systemic absorption or central activity involved.

Official Administration Guidelines for Keal (Sucralfate)

Keal, which contains the active ingredient sucralfate, is exclusively indicated for oral administration in both its tablet (1 gram) and oral suspension (1 gram per 10 mL) forms. Inappropriate intravenous (IV) administration is strongly cautioned against in regulatory labeling.

Dosage and Schedule

The standard adult oral dosage for the short-term treatment of active duodenal ulcers is 1 gram four times daily (QID). Treatment is typically continued for four to eight weeks, or until ulcer healing is confirmed. For maintenance therapy following the healing of acute ulcers, the recommended dose is 1 gram twice daily (BID).

Administration Conditions

To ensure proper function, Keal must be administered on an empty stomach. Official instructions direct the user to take the medication one hour before meals and at bedtime.

Furthermore, the following time-based constraints apply:

• Antacids may be used for pain relief but should not be taken within 30 minutes (one-half hour) before or after a dose of Keal.
• Other oral medications should be separated from Keal by at least 2 hours to avoid potential binding and reduced absorption of the co-administered drug.
• The oral suspension form must be shaken well before each dose is measured and taken.

Specific Population Rules

Official labels state that safety and efficacy have not been established in pediatric patients, and use in children under 14 is generally not recommended. For older adults, dose selection should be approached cautiously, often beginning at the lower end of the dosing range, due to the greater frequency of reduced organ function.

Research evidence / Overview of Studies for Keal

Evidence for use in Treating Active Gastric Ulcers

Keal was evaluated in studies exploring outcomes related to physical discomfort for conditions marked by functional limitations, specifically active gastric ulcers. Studies explored outcomes related to systemic or functional imbalance and outcomes describing episodic or acute changes in patients. The findings describe patterns observed in the studies and research describes how symptoms evolved in the observed populations during the initial treatment period. These studies help show what has been observed so far in populations studied for this condition, but research provides context but not individual predictions.

Evidence for use in Treating Active Duodenal Ulcers

Keal was evaluated in research contexts involving conditions characterized by fluctuating or episodic manifestations, such as active duodenal ulcers. Studies monitored patient-reported outcomes describing perceived discomfort and outcomes capturing phases of heightened symptom activity. The data show patterns related to outcomes related to systemic or functional imbalance that were observed in the research populations. Research highlights changes measured during the study period and helps contextualize how patients reported their experience.

Evidence for use in Preventing Duodenal Ulcer Recurrence

Research explored Keal's use in conditions involving periods of heightened symptoms to monitor recurrence of duodenal ulcers after initial healing. These studies observed responses over defined time intervals to see how the frequency of new symptoms changed. Findings indicate patterns related to outcomes describing episodic or acute changes that were monitored in the research. Studies contribute to the broader evidence landscape, but comparative evidence is lacking and certainty remains low regarding the full extent of long-term outcomes related to recurrence.

Long-term Studies and Follow-up

Information on outcomes of using Keal over extended periods is not fully established, and certainty remains low. Follow-up durations were limited in many studies, meaning there is limited information for outcomes extending beyond the initial treatment phase. Research highlights what is known—and what is still uncertain—about outcomes reflecting daily functioning or activity level in the long term. This section summarizes the available data from studies that monitored outcomes in the observed populations over defined time intervals, but long-term effects are not fully established.

Evidence in Special Populations

Evidence is limited regarding the use of Keal in certain groups. Studies exploring short-term symptom changes in populations such as older adults or those with comorbid health conditions (like liver or kidney issues) were modest in size. Data for certain groups remain insufficient, and research is ongoing to assess if the patterns observed in the main studies apply equally to all patient groups. Subgroup findings are uncertain, and results apply only to the populations studied in the research.

What is Still Uncertain About Keal

This section synthesizes the main evidence gaps and areas where more research is needed. Findings were mixed in some studies, and the certainty remains low regarding the full extent of outcomes measured in the studies. The research provides context but not individual predictions, and it highlights the areas where more research is needed to fully understand the evidence landscape for Keal.

Common questions about Keal (FAQ)

Q: How quickly does Keal start working after taking it?

Keal is a topical (surface-level) agent, and its action of forming a protective barrier occurs locally upon contact with the digestive lining. Official information indicates that the full course of treatment is usually continued for several weeks for complete ulcer healing.

Q: Is Keal an antibiotic?

No, according to official regulatory classification, Keal (sucralfate) is not an antibiotic. It is categorized as a gastrointestinal agent and a cytoprotective agent, meaning its primary function is to protect and support the healing of the digestive lining.

Q: What are the most commonly reported side effects of Keal?

Official prescribing information indicates that the most frequent complaint reported in clinical trials is constipation, which affected approximately 2% of patients. Other reactions reported infrequently included mild gastrointestinal issues such as dry mouth, nausea, vomiting, and diarrhea.

Q: How long do I need to take Keal?

The length of treatment is determined by a healthcare provider based on the patient's condition and whether the treatment is short-term or maintenance therapy. For active ulcers, the treatment course is typically continued for up to eight weeks.

Q: Is there a generic version of Keal available?

Yes, the active ingredient in Keal, sucralfate, is widely available as a generic drug. This generic form is approved and supplied in both tablet and oral suspension (liquid) forms.

Q: Does Keal cause weight gain or loss?

Changes in body weight, such as weight gain or weight loss, are not listed among the commonly reported or infrequent adverse effects documented in the official regulatory prescribing information for Keal.

Q: Can children use Keal, and at what age?

Official labeling states that the safety and effectiveness have not been established in the pediatric population (children under 18 years of age) for its approved uses. Use is restricted to adults for the approved indications.

Q: Are the side effects of Keal permanent?

The majority of adverse effects reported are generally minor and reversible. However, official safety information highlights that in patients with chronic kidney failure or those undergoing dialysis, there is a risk of severe, potentially long-lasting complications like aluminum toxicity due to impaired aluminum excretion.

Q: What happens if I miss a dose of Keal?

Instructions for a missed dose generally advise taking it as soon as it is remembered. If, however, it is nearly time for the next scheduled dose, the missed dose should be skipped. Patients are cautioned not to double the next dose to compensate for the missed one.

Q: Does Keal affect sleep patterns?

Official adverse reaction reports indicate that effects on the nervous system, such as insomnia (difficulty sleeping) and sleepiness, have been reported, though infrequently, among patients taking Keal.

Q: Can Keal make you tired or drowsy?

Sleepiness is listed as a nervous system adverse reaction reported in less than 0.5% of patients in clinical trials. If drowsiness is experienced, it is important to consult a healthcare professional.

Q: Can I stop taking Keal suddenly?

The medication is intended to be taken for the full prescribed duration to support complete healing of the ulcer. Any change to the regimen, including stopping the medication, should be made only under the guidance of a healthcare professional.

Q: What's the best time of day to take Keal?

Keal is required to be administered on an empty stomach for optimal function. The administration schedule typically involves taking the medication one hour before meals and a final dose at bedtime.

Q: Can I take vitamins and supplements while on Keal?

Keal can physically bind to and reduce the absorption of many other oral medicines, including vitamins and supplements. Official instructions advise separating Keal from other oral medications by at least two hours to help prevent this interaction.

Q: Does Keal cause headaches?

Headache is listed among the adverse reactions reported for sucralfate in post-marketing surveillance and clinical data.

Q: Are there any long-term effects of taking Keal?

For individuals with normal kidney function, risks related to extended use are typically considered low, but caution is still exercised. In patients with chronic kidney failure or those on dialysis, there is a risk of aluminum accumulation which can lead to severe toxic effects.

Q: Are there different strengths of Keal available?

Keal is supplied in a 1-gram tablet form and also as an oral suspension (liquid) which contains 1 gram of the active ingredient per 10 milliliters.

Q: Is Keal a relatively new medication?

The active ingredient in Keal, sucralfate, is a well-established medication that was first approved for use in the US before 1982.

Q: Is it important to take Keal with food?

No, it is explicitly stated in the administration conditions that Keal must be administered on an empty stomach. The typical instruction is to take the medication one hour prior to eating.

Q: Can men and women take the same Keal preparation?

Yes, the official prescribing information provides the same standard adult dosage for men and women for the treatment of active ulcers.

Q: Is Keal a controlled substance?

No, Keal (sucralfate) is not classified or scheduled as a controlled substance by the Drug Enforcement Administration (DEA).

Q: Are there different brand names for the same active ingredient as Keal?

Yes, the active ingredient, sucralfate, is also known by other brand names. One well-known example is Carafate, among others.

Q: Is there a maximum time someone can stay on Keal?

Short-term treatment for active ulcers is indicated for up to eight weeks. However, Keal is also approved for maintenance therapy, which has been studied and shown in controlled trials to be suitable for up to one year.

The storage and disposal of Keal (sucralfate) must strictly adhere to regulatory requirements to maintain product integrity and ensure safety.

Storage Requirements

Keal must be stored at Controlled Room Temperature, which ranges from 15°C to 30°C (59°F to 86°F). It is mandatory to keep the medicine in its original container and ensure the container is tightly closed to protect it from heat and moisture. The liquid oral suspension must not be frozen. Keal must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Keal should be disposed of via a drug take-back program if available. If a take-back option is not accessible, the product may be mixed with an undesirable substance (like coffee grounds), sealed in a bag, and discarded in household trash. Do not flush Keal down a toilet or pour it down a sink.